




Searching News Database: Alzheimer's disease
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
HSMN NewsFeed - 24 Jun 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 1 May 2019
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
HSMN NewsFeed - 1 Nov 2018
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
HSMN NewsFeed - 23 Aug 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
HSMN NewsFeed - 9 Jul 2018
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HSMN NewsFeed - 12 Jun 2018
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
HSMN NewsFeed - 12 Jul 2017
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
HSMN NewsFeed - 9 Dec 2016
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
HSMN NewsFeed - 28 Oct 2016
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 12 May 2016
Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
HSMN NewsFeed - 16 Feb 2016
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
HSMN NewsFeed - 21 Oct 2015
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
HSMN NewsFeed - 8 May 2014
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 16 Dec 2013
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 7 May 2013
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
HSMN NewsFeed - 14 Nov 2012
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
HSMN NewsFeed - 9 Dec 2011
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
HSMN NewsFeed - 16 Aug 2011
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
HSMN NewsFeed - 9 May 2011
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
HSMN NewsFeed - 24 Mar 2011
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
HSMN NewsFeed - 8 Feb 2011
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic Imaging
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic Imaging
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 14 Jan 2011
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
HSMN NewsFeed - 16 Aug 2010
Curaxis Pharmaceutical Corp Elects Dr. Bert A. Spilker to Board of Directors
Curaxis Pharmaceutical Corp Elects Dr. Bert A. Spilker to Board of Directors
HSMN NewsFeed - 11 Aug 2010
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
HSMN NewsFeed - 13 Jul 2010
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
HSMN NewsFeed - 9 Feb 2010
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
HSMN NewsFeed - 18 Mar 2009
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
HSMN NewsFeed - 10 Mar 2009
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
HSMN NewsFeed - 6 Feb 2009
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
HSMN NewsFeed - 4 Feb 2009
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
HSMN NewsFeed - 8 Jan 2009
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
HSMN NewsFeed - 28 Oct 2008
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer’s Disease Study
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer’s Disease Study
HSMN NewsFeed - 17 Sep 2008
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
HSMN NewsFeed - 31 Mar 2008
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
HSMN NewsFeed - 13 Mar 2008
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
HSMN NewsFeed - 12 Mar 2008
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
HSMN NewsFeed - 20 Feb 2008
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
HSMN NewsFeed - 28 Dec 2007
Transition Therapeutics Announces Appointment of Vice-President of Business Development
Transition Therapeutics Announces Appointment of Vice-President of Business Development
HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem announces important initiatives to provide medical and health benefits to patients
HSMN NewsFeed - 10 Oct 2007
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
HSMN NewsFeed - 25 Sep 2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
HSMN NewsFeed - 28 Aug 2007
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
HSMN NewsFeed - 19 Jun 2007
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
HSMN NewsFeed - 18 Jun 2007
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
HSMN NewsFeed - 18 Jun 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
HSMN NewsFeed - 4 Jun 2007
Avid Radiopharmaceuticals Appoints Ernest Mario, Ph.D. to Board of Directors
Avid Radiopharmaceuticals Appoints Ernest Mario, Ph.D. to Board of Directors
HSMN NewsFeed - 31 May 2007
Abiomed Appoints Eric A. Rose, M.D., a Leader in Circulatory Care, to Its Board of Directors
Abiomed Appoints Eric A. Rose, M.D., a Leader in Circulatory Care, to Its Board of Directors
HSMN NewsFeed - 21 May 2007
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
HSMN NewsFeed - 17 May 2007
DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
HSMN NewsFeed - 2 May 2007
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 23 Apr 2007
Prana Expands Senior Management Team with Appointment of Two US-based Pharmaceutical Executives
Prana Expands Senior Management Team with Appointment of Two US-based Pharmaceutical Executives
HSMN NewsFeed - 10 Apr 2007
New BIO Study Confirms Innovative Therapies Will Have Minimal Impact on Healthcare Costs
New BIO Study Confirms Innovative Therapies Will Have Minimal Impact on Healthcare Costs
HSMN NewsFeed - 3 Apr 2007
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
HSMN NewsFeed - 20 Mar 2007
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
HSMN NewsFeed - 19 Mar 2007
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
HSMN NewsFeed - 6 Mar 2007
Applied NeuroSolutions Hires Top Ranked Analyst, Ryan Rauch, to Direct its Investor Relations Program
Applied NeuroSolutions Hires Top Ranked Analyst, Ryan Rauch, to Direct its Investor Relations Program
HSMN NewsFeed - 5 Mar 2007
Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
HSMN NewsFeed - 1 Feb 2007
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
HSMN NewsFeed - 11 Jan 2007
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
HSMN NewsFeed - 4 Dec 2006
Merck and Neuroptix Collaborate on Early Alzheimer's Diagnostics Using Laser Eye Scanning
Merck and Neuroptix Collaborate on Early Alzheimer's Diagnostics Using Laser Eye Scanning
HSMN NewsFeed - 27 Nov 2006
Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights
Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights
HSMN NewsFeed - 9 Nov 2006
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
HSMN NewsFeed - 9 Nov 2006
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
HSMN NewsFeed - 2 Nov 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
HSMN NewsFeed - 24 Oct 2006
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
HSMN NewsFeed - 13 Oct 2006
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
HSMN NewsFeed - 11 Oct 2006
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
HSMN NewsFeed - 21 Sep 2006
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
HSMN NewsFeed - 14 Sep 2006
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
HSMN NewsFeed - 22 Aug 2006
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
HSMN NewsFeed - 22 Aug 2006
Myriad Genetics Completes Enrollment in U.S. Phase 3 Clinical Trial of Flurizan for Alzheimer's Disease
Myriad Genetics Completes Enrollment in U.S. Phase 3 Clinical Trial of Flurizan for Alzheimer's Disease
HSMN NewsFeed - 1 Aug 2006
FDA Provides Clearance to Initiate Phase I Clinical Trial with Alzheimer's Disease Drug Product AZD-103
FDA Provides Clearance to Initiate Phase I Clinical Trial with Alzheimer's Disease Drug Product AZD-103
HSMN NewsFeed - 28 Jul 2006
Pfizer Board of Directors Names Jeffrey B. Kindler Chief Executive Officer
Pfizer Board of Directors Names Jeffrey B. Kindler Chief Executive Officer
HSMN NewsFeed - 28 Jul 2006
FDA Extends Review of EPIX Pharmaceuticals' Appeal of Vasovist(TM) Approvable Letters
FDA Extends Review of EPIX Pharmaceuticals' Appeal of Vasovist(TM) Approvable Letters
HSMN NewsFeed - 19 Jul 2006
Applied NeuroSolutions Announces Intent of John F. DeBernardis to Resign as CEO
Applied NeuroSolutions Announces Intent of John F. DeBernardis to Resign as CEO
HSMN NewsFeed - 19 Jul 2006
Myriad's 24-Month Study of Flurizan Demonstrates Significant Benefit in Alzheimer's Disease Patients
Myriad's 24-Month Study of Flurizan Demonstrates Significant Benefit in Alzheimer's Disease Patients
HSMN NewsFeed - 6 Jul 2006
Cardinal Health Acquires Positron Emission Tomography (PET) Radiopharmaceutical Production Facilities
Cardinal Health Acquires Positron Emission Tomography (PET) Radiopharmaceutical Production Facilities
HSMN NewsFeed - 30 Jun 2006
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
HSMN NewsFeed - 20 Jun 2006
U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's Disease
U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's Disease
HSMN NewsFeed - 19 May 2006
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
HSMN NewsFeed - 8 May 2006
VSM reports progress on using MEG for diagnosing Alzheimer's and Parkinson's
VSM reports progress on using MEG for diagnosing Alzheimer's and Parkinson's
HSMN NewsFeed - 8 May 2006
Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
HSMN NewsFeed - 3 May 2006
Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study for Alzheimer's Disease
Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study for Alzheimer's Disease
HSMN NewsFeed - 17 Apr 2006
BrainLAB iPlan(R) Flow Software Opens New Avenues for Delivering Drugs to the Brain
BrainLAB iPlan(R) Flow Software Opens New Avenues for Delivering Drugs to the Brain
HSMN NewsFeed - 21 Mar 2006
Neuro-Hitech Pharmaceuticals, Inc. Signs Alzheimer's Transdermal Development Agreement with Xel
Neuro-Hitech Pharmaceuticals, Inc. Signs Alzheimer's Transdermal Development Agreement with Xel
HSMN NewsFeed - 12 Mar 2006
Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
HSMN NewsFeed - 8 Mar 2006
Statin Drug Potential for Alzheimer's Disease Gains Ground with Recent Studies
Statin Drug Potential for Alzheimer's Disease Gains Ground with Recent Studies
HSMN NewsFeed - 28 Feb 2006
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
HSMN NewsFeed - 9 Feb 2006
Nymox's Alzheimer Drug Programs Generate Several Novel Product Developments
Nymox's Alzheimer Drug Programs Generate Several Novel Product Developments
HSMN NewsFeed - 31 Jan 2006
Mark A. Varney, Ph.D. Named Chief Operating Officer and Chief Scientific Officer of Cortex Pharmaceuticals
Mark A. Varney, Ph.D. Named Chief Operating Officer and Chief Scientific Officer of Cortex Pharmaceuticals
HSMN NewsFeed - 23 Jan 2006
Neuroptix Announces Successful Angel Investment Round Led by Launchpad Venture Group
Neuroptix Announces Successful Angel Investment Round Led by Launchpad Venture Group
HSMN NewsFeed - 20 Jan 2006
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
HSMN NewsFeed - 4 Jan 2006
Axonyx Announces License of Phenserine to Daewoong Pharmaceutical Company for South Korea
Axonyx Announces License of Phenserine to Daewoong Pharmaceutical Company for South Korea
Additional items found! 238

Members Archive contains
238 additional stories matching:
Alzheimer's disease
(Password required)
Alzheimer's disease
(Password required)